~~<i id='8B5BA150B2'><strike id='8B5BA150B2'><tt id='8B5BA150B2'><pre id='8B5BA150B2'></pre></tt></strike></i>~~

Home» focus» comprehensive

comprehensive

author：knowledge 2025-10-06 11:09:33 Page View：8

Editor’s note: A recording of the event is embedded below.

After a few go-go years, the early-stage biotech market has cooled considerably. Two VCs will weigh in on what distinguishes great science from bad investments.

Featured Speakers

Irena Melnikova, Ph.D., partner, Pfizer Ventures
Rakhshita Dhar, senior director, venture investments, Leaps by Bayer
Frank S. David, M.D., Ph.D., managing director, Pharmagellan (moderator)

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Readout Newsletter: Amylyx, Aurinia, and IQVIA
Next article： Affirmative action in medical school literally saved lives

focus

Drug repurposing or repositioning? The language matters

AdobeFindinganewmedicineisnevereasy.Butdevelopingtreatmentsforpatientswithrarediseases—conditionstha

Tome Biosciences co

SuzanneKreiter/GlobestaffWATERTOWN—TheirbrainstormingbeganinanMITclassin2010whentheeagerundergradssh

The high cost of giving birth even with insurance

AdobeTheburdenofhighhealthcarecostsandmedicaldebtintheU.S.isnosecret.Medicaldebtaffectsoneinfiveadul

Review: 'Barbie' will hit you like a shot in the heart

6:22RyanGosling,left,asKenandMargotRobbieasBarbieareseeninastillfromWarnerBros.Pictures'"Barbie."Cou